National Reference Standards for vaccines released

The Indian Pharmacopeia Commission (IPC) has released the national reference standards, specifically referred as the Indian Pharmacopoeia Reference Substances (IPRS Vaccines), the first such initiative to be undertaken of its kind. The standards would include IP monographs which act as the national reference standards for vaccines. 

 

June 07, 2016: The Indian Pharmacopeia Commission (IPC) has released the national reference standards, specifically referred as the Indian Pharmacopoeia Reference Substances (IPRS Vaccines), the first such initiative to be undertaken of its kind. The standards would include IP monographs which act as the national reference standards for vaccines. 

 

Vaccines are biological preparations that help in stimulating the body’s immune system thereby protecting the body against any infectious disease. Therefore vaccines are more important than the use of prophylaxis. 

 

The standards were released on the occasion of the 5th Expert Committee Meeting held in Kasauli, Himachal Pradesh, jointly organised by IPC and Central Drugs Laboratory (CDL). Representatives from D rug Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO) and Central Research Institute (CRI) were also present. Other related participants included stakeholders from vaccine manufacturing companies and representatives from PETA.

 

IPC has been working on the quality standards of drugs, vaccines and formulations and has been working with CDL,the national control laboratory for vaccines. It has been working on the quality standards of drugs and its formulations and has been coming up with the regular editions of the Indian Pharmacopoeia (IP). The IPC has emphasised its interest in specifically focusing on standards for ‘vaccines and immunosera’ for human use. 

 

Also, related to the development of vaccines, The Department of Biotechnology ( DBT) would be investing  INR 1000 crore (US $ 153 million) to enhance and improve the existing centres for drug discovery and vaccine research in India. DBT has been working on international collaboration in vaccines and finding ways to address the problem of anti-microbial resistance. The government envisions the biotechnology sector to reach US$ 100 billion by 2025.

 

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...